posted on 2023-03-30, 22:52authored byLu Deng, Li Shang, Shoumin Bai, Ji Chen, Xueyan He, Rachel Martin-Trevino, Shanshan Chen, Xiao-yan Li, Xiaojie Meng, Bin Yu, Xiaolin Wang, Yajing Liu, Sean P. McDermott, Alexa E. Ariazi, Christophe Ginestier, Ingrid Ibarra, Jia Ke, Tahra Luther, Shawn G. Clouthier, Liang Xu, Ge Shan, Erwei Song, Herui Yao, Gregory J. Hannon, Stephen J. Weiss, Max S. Wicha, Suling Liu
<p>Figure S1. Comparison of ALDH-positive population in different breast cancer cell lines and primary xenografts (UM2, MC1, UM1). Figure S2. mir-100 overexpression decreases ki67+ population in vitro. Figure S3. mir-100 overexpression inhibits the proliferation of both ALDH+ population and ALDH- population. Figure S4. mir-100 inhibits tumor growth of SUM149, MCF7 and T47D in NOD/SCID mice. Figure S5. mir-100 expression is higher in the tumor cells from mir-100 group compared to that from CTRL group. Figure S6. The percentage of ALDH+ cells in both primary CTRL and secondary CTRL tumors were increased compared to the parental cells injected. Figure S7. mir-100 expression is higher in the tumor cells from mir-100 induction groups with DOX (Late and Early) compared to that from CTRL group. Figure S8. mir-100 overexpression is necessary to maintain the inhibition of SUM159 tumor growth in NOD/SCID mice. Figure S9. mir-100 knockdown increases tumor growth in vivo. Figure S10. mir-100 inhibits metastasis of Both Total (Unseparated) and ALDH+ SUM159 cells in vivo. Figure S11. Identification of direct targets of mir-100. Figure S12. Knockdown of mir-100 targets mimic the effects of mir-100 overexpression. Figure S13. Verification of SMARCA5 and SMARCD1 level by Western blot. Figure S14. SMARCA5 and SMARCD1 are direct and functional targets of mir-100 in SUM149 cells. Figure S15. Kaplan-Meier survival curves based on the expression of SMARCA5 and SMARCD1.</p>